CVS Health upgraded by TD Cowen with a new price target
$CVS
Retail-Drug Stores and Proprietary Stores
Consumer Staples
TD Cowen upgraded CVS Health from Hold to Buy and set a new price target of $85.00 from $59.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $91.00 | Buy | Goldman |
| 8/18/2025 | $79.00 | Neutral → Buy | UBS |
| 8/14/2025 | $82.00 | Neutral → Outperform | Robert W. Baird |
| 2/13/2025 | $55.00 → $75.00 | Market Perform → Outperform | Leerink Partners |
| 2/12/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 1/30/2025 | Hold → Buy | Edward Jones | |
| 12/3/2024 | $66.00 | Hold → Buy | Deutsche Bank |
| 11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo |
10-Q - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
3/A - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00
UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00
Robert W. Baird upgraded CVS Health from Neutral to Outperform and set a new price target of $82.00
Financial Highlights Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior yearThird quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unitThird quarter Adjusted EPS of $1.60Generated year-to-date cash flow from operations of $7.2 billionOperational Highlights Aetna® receives industry-leading Medicare Advantage Star Ratings resultsLaunch of annual vaccination campaign at CVS Pharmacy® and MinuteClinic® locations nationwideCaremark® closes out another strong selling season with contract wins totaling nearly $6.0 billion and retention in the high nineties
WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (
Company wraps up conversion of 63 former Rite Aid and Bartell Drugs stores in the Pacific Northwest and hundreds of prescription file buys across 15 states WOONSOCKET, R.I., Oct. 15, 2025 /PRNewswire/ -- CVS Pharmacy today announced the completion of its acquisition of select Rite Aid assets nationwide. In total, the company acquired and is now operating 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington. CVS Pharmacy also acquired the prescription files of 626 former Rite Aid and Bartell Drugs pharmacies in 15 states. As a result of the transactions, CVS Pharmacy is pleased to be serving more than nine million former Rite Aid and Bartell Drugs patients.
Financial Highlights Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior yearThird quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unitThird quarter Adjusted EPS of $1.60Generated year-to-date cash flow from operations of $7.2 billionOperational Highlights Aetna® receives industry-leading Medicare Advantage Star Ratings resultsLaunch of annual vaccination campaign at CVS Pharmacy® and MinuteClinic® locations nationwideCaremark® closes out another strong selling season with contract wins totaling nearly $6.0 billion and retention in the high nineties
Company wraps up conversion of 63 former Rite Aid and Bartell Drugs stores in the Pacific Northwest and hundreds of prescription file buys across 15 states WOONSOCKET, R.I., Oct. 15, 2025 /PRNewswire/ -- CVS Pharmacy today announced the completion of its acquisition of select Rite Aid assets nationwide. In total, the company acquired and is now operating 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington. CVS Pharmacy also acquired the prescription files of 626 former Rite Aid and Bartell Drugs pharmacies in 15 states. As a result of the transactions, CVS Pharmacy is pleased to be serving more than nine million former Rite Aid and Bartell Drugs patients.
WOONSOCKET, R.I., Sept. 30, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, October 29th, 2025, at 8:00 a.m. ET to discuss third quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of June 30, 2025,
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (
Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi
WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res